68ga-nota-nectin-4 antibody fragment
Lung Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyradiopharmaceuticalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
67 Active assets in the Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Taiho Oncology, Inc. | Phase 3 | BB |
OTL-38 On Target Laboratories, LLC | Phase 4 | BB |
ETOPOSIDE SystImmune Inc. | Phase 3 | BB |
Nivolumab M.D. Anderson Cancer Center | Phase 2 | B |
Carboplatin SystImmune Inc. | Phase 3 | B |
View all 50 →
Same molecule, other indications
68ga-nota-nectin-4 antibody fragment is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →